These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11195053)

  • 1. Implications from the Heart Outcomes Prevention Evaluation Study.
    Weir MR; Blantz RC
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):61-3. PubMed ID: 11195053
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood pressure and cardiovascular risk in the HOPE study.
    Taylor R
    Lancet; 2002 Jun; 359(9323):2117-8; author reply 2118. PubMed ID: 12086795
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 6. The Heart Outcomes Protection Evaluation (HOPE) study: relevance to ophthalmological practice?
    Barnett AH
    Eye (Lond); 2000 Feb; 14 ( Pt 1)():1-2. PubMed ID: 10755090
    [No Abstract]   [Full Text] [Related]  

  • 7. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.
    Marshall SM
    Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826
    [No Abstract]   [Full Text] [Related]  

  • 8. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
    Sica DA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):597-601. PubMed ID: 11496052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis.
    Xie W; Zheng F; Evangelou E; Liu O; Yang Z; Chan Q; Elliott P; Wu Y
    J Hypertens; 2018 Jun; 36(6):1256-1265. PubMed ID: 29543625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE?
    Ferrari R
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):11-2. PubMed ID: 16649066
    [No Abstract]   [Full Text] [Related]  

  • 11. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.
    ; Turnbull F; Neal B; Pfeffer M; Kostis J; Algert C; Woodward M; Chalmers J; Zanchetti A; MacMahon S
    J Hypertens; 2007 May; 25(5):951-8. PubMed ID: 17414657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who is fooling us?
    Sleight P; Yusuf S
    Lancet; 2002 Sep; 360(9336):873-4. PubMed ID: 12243941
    [No Abstract]   [Full Text] [Related]  

  • 14. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent review highlights implications for prevention of cardiovascular disease.
    Cardiovasc J S Afr; 2003; 14(3):161-2. PubMed ID: 12931737
    [No Abstract]   [Full Text] [Related]  

  • 16. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
    Nilsson PM; Cifkova R; Kjeldsen SE
    J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
    [No Abstract]   [Full Text] [Related]  

  • 18. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
    Voors AA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
    [No Abstract]   [Full Text] [Related]  

  • 19. Blood-pressure reduction and cardiovascular risk in HOPE study.
    Sleight P; Yusuf S; Pogue J; Tsuyuki R; Diaz R; Probstfield J;
    Lancet; 2001 Dec 22-29; 358(9299):2130-1. PubMed ID: 11784631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of treatment of hypertension on cardiovascular outcome in type 2 diabetes.
    Migdalis IN
    Res Commun Mol Pathol Pharmacol; 2006; 119(1-6):105-14. PubMed ID: 17974100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.